Anti-angiogenic therapies in cancer clinical trials

Bibliography

• SPEED MP: Angiogenesis inhibition as a drug target for disease: an update. Exp. Opin. Invest. Drugs (1996) 5(12):1617–1637.
   Google Scholar
• ••An earlier update of reviews on anti-angiogenic agents indevelopment and trial.
   Google Scholar
• CASEY R, LI WW, LI VW: Angiogenesis in malignancy. Future Oncol. (1995) 1 (7/8) :185–199.
   Google Scholar
• ••Comprehensive review on (anti-)angiogenesis with infor-mation on major developers of anti-angiogenic agents.
   Google Scholar
• FOX SB, GATTER KC, HARRIS AL: Tumour angiogenesis. Pathol. (1996) 179:232–237.
   Web of Science ®Google Scholar
• •Review of clinical studies measuring vascular density.
   Google Scholar
• RAK J, MITUHASHI Y, BAYKO L et al. Mutant ras onco-genes up-regulate VEGF/VPF expression - implications for induction and inhibition of tumour angiogenesis. Cancer Res. (1995) 55:4574–4580.
   Google Scholar
• BREM S: Angiogenesis antagonists: current clinical tri- als. Angiogenesis (1998) 2(1):9–20.
   PubMedGoogle Scholar
• ••Recent meeting report on anti-angiogenic clinical trials andrelated regulatory issues.
   Google Scholar
• MASIERO L, FIGG W, KOHN EC: New anti-angiogenesisagents: review of the clinical experience with carboxyamido-triazole (CAO, thalidomide, TNP-470 and interleukin-12. Angiogenesis (1997) 1 (1):23–35.
   PubMedGoogle Scholar
• TWARDOWSKI P, GRADISHAR WJ: Clinical trials of anti-angiogenic agents. Curr. Opin. Oncol. (1997) 9(6)584–589.
   Google Scholar
• GASPARINI G: Antiangiogenic drugs as a novel antican-cer therapeutic strategy. Which are the more promis-ing agents? What are the clinical developments and indications? Crit. Rev. Oncol. Hematol. (1997) 26(3)147–162.
   Google Scholar
• MARSHALL JL, HAWKINS MJ: The clinical experiencewith antiangiogenic agents. Breast Cancer Res. Treat. (1995) 36(2):253–261.
   PubMed Web of Science ®Google Scholar
• KUIPER RA, SCHELLENS JH, BLIJHAM GH, BEIJNEN JH,VOEST EE: Clinical research on antiangiogenic ther-apy. Pharmacol Res. (1998) 37(0:1–16.
   PubMedGoogle Scholar
• LE SERVE AW, HELLMANN K: Metastases and the nor-malization of tumour blood vessels by ICRF 159: a new type of drug action. Br. Med. J. (1972) 1:597–601.
   PubMed Web of Science ®Google Scholar
• HELLMANN K: Cardioprotection by dexrazoxane (car-dioxane; ICRF 187): progress in supportive care. Sup-port. Care Cancer (1996) 4:305–307.
   PubMed Web of Science ®Google Scholar
• ELIHU N, ANANDASBAPATHY S, FRISHMAN WH: Chela-tion therapy in cardiovascular disease: ethylenediami-netetraacetic acid, desferoxamine, and dexrazoxane. Clin. Pharmacol. (1998) 38 (2) :101–105.
   Google Scholar
• HASINOFF BB, HELLMANN K, HERMAN EH, FERRANS VJ: Chemical, biological and clinical aspects of dexrazox-ane and other bisdioxopiperazines. Curr. Merl. Chem. (1998) 5(0:1–28.
   PubMedGoogle Scholar
• ••Background review on chemical, biological and clinical as-pects of dexrazoxane.
   Google Scholar
• TYRELL DJ, KILFEATHER S, PAGE CP: Therapeutic uses of heparin beyond its traditional role as an anticoagu- lant. Trends Pharmacol. Sci. (1995) 16(6):198–204.
   PubMed Web of Science ®Google Scholar
• ••Background review of heparin and its therapeutic uses.
   Google Scholar
• HUNT D: Low-molecular-weight heparins in clinical practice. South Med. J. (1998) 91(0:2–10.
   PubMedGoogle Scholar
• ••Background review of low molecular weight heparin andtheir therapeutic uses.
   Google Scholar
• TURPIE AG: Low-molecular-weight heparins and un-stable angina - current perspectives. Haemostasis (1997) 27\(Suppl. 0:19–24.
   Google Scholar
• TING SB, ZIEGENBEIN RW, GAN TE et al.: Dalteparin for deep venous thrombosis: a hospital-in-the-home pro-gram. Med. J. Aust. (1998) 168 (6) :272–276.
   PubMed Web of Science ®Google Scholar
• TYRRELL DJ, ISHIHARA M, RAO N et al.: Structure and biological activities of a heparin-derived hexasaccha-ride with high affinity for basic fibroblast growth fac-tor. J. Biol. Chem. (1993) 268(7):4684–4689.
   PubMed Web of Science ®Google Scholar
• WILLIAMS PD, YE H, CHENG FC, FUGEDI P, TRESSLER R:Comparative effects of heparin and the sulfatoid GM1474 on coagulation parameters in plasma and blood from various species. Gen. Pharmacol. (1998) 30(3):337–341.
   PubMedGoogle Scholar
• CABANES A, BRIGGS KE, GOKHALE PC, TREAT JA, RAH-MAN A: Comparative in vivo studies with paclitaxel and liposome-encapsulated paclitaxel. Int. J. Oncol (1998) 12(5):1035–1040.
   PubMed Web of Science ®Google Scholar
• WISEMAN LR, SPENCER CM: Paclitaxel. An update of its use in the treatment of metastatic breast cancer and ovarian and other gynaecological cancers. Drugs Aging (1998) 12(4):305–334.
   Google Scholar
• ••An update of therapeutic uses of paclitaxel.
   Google Scholar
• KLAUBER N, PARANGI S, FLYNN E, HAMEL E, D'AMATO RJ: Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res. (1997) 57 (1):81–86.
   PubMed Web of Science ®Google Scholar
• NCI: Paclitaxel: PDQ drug information for health pro-fessionals.http://www.graylab.ac.uk/cancer-fessionals.http://www.graylab.ac.uk/cancer-net/802424.html (last modified May 1996).
   Google Scholar
• ••Comprehensive review on paclitaxel for professionals.
   Google Scholar
• SPENCER CM, FAULDS D: Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer. Drugs (1994) 48(5):794–847.
   Google Scholar
• VAUGHN DJ, MALKOWICZ SB, ZOTICK B et al.: Paclitaxel plus carboplatin in advanced carcinoma of the uroth-IMm: an active and tolerable outpatient regimen. J. Clin. Oncol. (1998) 16:255–260.
   PubMed Web of Science ®Google Scholar
• BOYLAN M, VAN DEN BERG HW, LYNCH M: The anti-proliferative effect of suramin towards tamoxifen-sensitive and resistant human breast cancer cell lines in relation to expression of receptors for epidermal growth factor and insulin-like growth factor-I: growth stimulation in the presence of tamoxifen. Ann. Oncol. (1998) 9(2):205–211.
   PubMed Web of Science ®Google Scholar
• ZHANG YL, KENG YF, ZHAO Y, WU L, ZHANG ZY: Su-ramin is an active site-directed, reversible, and tight-binding inhibitor of protein-tyrosine phosphatases. J. Biol. Chem. (1998) 273(20:12281–12287.
   PubMed Web of Science ®Google Scholar
• ••Recent paper on the machanisms of suramin action.
   Google Scholar
• KEHINDE EO, TERRY TR, MISTRY N et al.: UK studies on suramin therapy in hormone resistant prostate can-cer. Cancer Surv. (1995) 23:217–229.
   PubMedGoogle Scholar
• ••Review of clinical studies of suramin in the UK.
   Google Scholar
• ROSEN P, BELLDEGRUN A: American studies on su-ramin therapy in hormone resistant prostate cancer. Cancer Surv. (1995) 23:231–234.
   PubMedGoogle Scholar
• ••Review of clinical studies of suramin in the USA.
   Google Scholar
• MOTZER RJ, NANUS DM, ()MOORE P et al. Phase II trial of suramin in patients with advanced renal cell carci-noma: treatment results, pharmacokinetics, and tu-mor growth factor expression. Cancer Res. (1992) 52(20)5775–5779.
   Google Scholar
• WALTHER MM, FIGG WD, LINEHAN WM: Intravesical su- ramin: a novel agent for the treatment of superficial transitional-cell carcinoma of the bladder. World J. Urol. (1996) 14\(Suppl. 1):58–S11.
   Google Scholar
• BERGAN RC, WALLS RG, FIGG WD et al. Similar clinical outcomes in African-American and non-African-American males treated with suramin for metastatic prostate cancer. J. Natl. Med. Assoc. (1997) 89(9) 622–628
   PubMed Web of Science ®Google Scholar
• DAWSON NA, FIGG WD, COOPER MR et al.: Phase II trialof suramin, leuprolide, and flutamide in previously untreated metastatic prostate cancer. J. Clin. Oncol (1997) 15(4):1470–1477.
   PubMed Web of Science ®Google Scholar
• BOWDEN CJ, FIGG WD, DAWSON NA et al.: A Phase I/IIstudy of continuous infusion suramin in patients with hormone-refractory prostate cancer: toxicity and re-sponse. Cancer Chem other. Pharmacol (1996) 39(1-2):1–8.
   PubMed Web of Science ®Google Scholar
• EISENBERGER MA, SINIBALDI VJ, REYNO LM eta].: Phase Iand clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer. J. Clin. Oncol. (1995) 13 (9):2174–2186.
   Google Scholar
• BRADDOCK PS, HU DE, FAN TP et al.: A structure-activity analysis of antagonism of the growth factor and angio-genic activity of basic fibroblast growth factor by su-ramin and related polyanions. Br. J. Cancer (1994) 69(5) :890–898.
   PubMed Web of Science ®Google Scholar
• ••Source paper of structure-activity studies on suraminanalogues.
   Google Scholar
• GAGLIARDI AR, KASSACK M, KREIMEYER A et al: Antian- giogenic and antiproliferative activity of suramin ana-logues. Cancer Chemother. Pharmacol. (1998) 41(2):117–124.
   PubMed Web of Science ®Google Scholar
• ••Recent paper on structure-activity of 70 suramin analogues.
   Google Scholar
• DEZUBE BJ, VON ROENN JH, HOLDEN-WILTSE J et al.:Fumagillin analog in the treatment of Kaposi's sar-coma: a Phase I AIDS Clinical Trial Group study. AIDS Clinical Trial Group No. 215 Team. J. Clin. Oncol (1998) 16 (4): 1444–1449.
   Google Scholar
• FIGG WD, PLUDA JM, LUSH RM et al.: The pharmacoki-netics of TNP-470, a new angiogenesis inhibitor. Phar-macotherapy (1997) 17(0:91–97.
   PubMedGoogle Scholar
• KUDELKA AP, VERSCHRAEGEN CF, LOYER E: Complete remission of metastatic cervical cancer with the angio-genesis inhibitor TNP-470. New Engl. J. Med. (1998) 338 (14):991–992.
   PubMed Web of Science ®Google Scholar
• SIN N, MENG L, WANG MQ et al: The anti-angiogenic agent fumagillin covalently binds and inhibits the me-thionine aminopeptidase, MetAP-2. Proc. Natl. Acad. Sci. USA (1997) 94(12):6099–6103.
   PubMed Web of Science ®Google Scholar
• ••Recent mechanistic study on AGM-470 showing that MetAP2is an important target for anti-angiogenic drugs.
   Google Scholar
• GRIFFITH EC, SU Z, TURK BE et al.: Methionine amino- peptidase (type 2) is the common target for angiogene-sis inhibitors AGM-1470 and ovalicin. Chem. Biol. (1997) 4(6):461–471.
   PubMed Web of Science ®Google Scholar
• ••Recent mechanistic study on AGM-470 showing that MetAP2is an important target for anti-angiogenic drugs.
   Google Scholar
• SILVA HT, Jr., MORRIS RE: Leflunomide and malononi- trilamides. Am. J. Med. Sci. (1997) 313(5):289–301.
   PubMedGoogle Scholar
• ••Background review on leflunomide and its metabolites.
   Google Scholar
• WOJTOWICZ-PRAGA SM, DICKSON RB, HAWKINS MJ: Matrix metalloproteinase inhibitors. Invest. New Drugs (1997) 15:61–75.
   PubMed Web of Science ®Google Scholar
• ••Comprehensive review of MMP inhibitors in relation to drugdevelopment.
   Google Scholar
• RASMUSSEN HS, MCCANN PP: Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat. Pharma-col. Ther. (1997) 75:(1):69–75.
   PubMed Web of Science ®Google Scholar
• ••Comprehensive review of preclinical and clinical data onbatimastat and marimastat as prototype MMP inhibitors in the cancer area.
   Google Scholar
• MILLAR A, BROWN PB: 360 Patients meta-analysis ofstudies of marimastat: a novel matrix metalloprote-inase inhibitor. Ann. Oncol. (1996) 7 (Suppl. 5):123.
   Google Scholar
• GORE M, A'HERN R, STANKIEWICZ M, SLEVIN M: Tumourmarker levels during marimastat therapy. Lancet (1996)348:263.
   PubMed Web of Science ®Google Scholar
• DUPONT E, SAVARD PE, JOURDAIN C et al.: Antiangio-genic properties of a novel shark cartilage extract: po-tential role in the treatment of psoriasis. J. Cutan. Med. Surg. (1998) 2(3):146–152.
   PubMedGoogle Scholar
• ••First peer-reviewed paper on AE-941.
   Google Scholar
• LANGER R, BREM H, FALTERMAN K, KLEIN M, FOLKMAN J: Isolation of a cartilage factor that inhibits tumor neo-vascularization. Science (1976) 193 (4247):70–72.
   PubMed Web of Science ®Google Scholar
• ERNST E: Shark cartilage for cancer? Lancet (1998) 351(9098)298.
   Web of Science ®Google Scholar
• ••A recent correspondence on shark-cartilage products on themarket and cancer patient management.
   Google Scholar
• KOHN EC, REED E, SAROSY G et al: Clinical investiga-tion of a cytostatic calcium influx inhibitor in patients with refractory cancers. Cancer Res. (1996) 56(3)569–573.
   Google Scholar
• KOHN EC, FIGG WD, SAROSY GA et al: Phase I trial ofmicronized formulation carboxyamidotriazole in patients with refractory solid tumors: pharmacokinet-ics, clinical outcome, and comparison of formula-tions. J. Clin. Oncol. (1997) 15(5):1985–1993.
   PubMed Web of Science ®Google Scholar
• BERLIN J, TUTSCH KD, HUTSON P et al.: Phase I clinicaland pharmacokinetic study of oral carboxyamidotria-zole, a signal transduction inhibitor. J. Clin. Oncol (1997) 15(2):781–789.
   PubMed Web of Science ®Google Scholar
• LORUSSO PM, DEMCHIK L, FOSTER B et al: Preclinicalantitumor activity of CI-994. Invest. New Drugs (1996) 14 (4):349–356.
   PubMed Web of Science ®Google Scholar
• EL-BELTAGI HM, MARTENS AC, LELIEVELD P, HAROUN EA, HAGENBEEK A: Acetyldinaline: a new oral cyto-static drug with impressive differential activity against leukemic cells and normal stem cells - preclinical stud-ies in a relevant rat model for human acute myelocytic leukemia. Cancer Res. (1993) 53 (13) 3008–3014.
   PubMed Web of Science ®Google Scholar
• GRAZIANO MJ, PILCHER GD, WALSH KM, KASALI OB, RADULOVIC L: Preclinical toxicity of a new oral anti-cancer drug, CI-994 (acetyldinaline), in rats and dogs. Invest. New Drugs (1997) 15(4):295–310.
   PubMed Web of Science ®Google Scholar
• HELLERQVIST CG, THURMAN GB, PAGE DL et al.: Antitu-mor effects of GBS toxin: a polysaccharide exotoxin from group B beta-hemolytic streptococcus. J. Cancer Res. Clin. Oncol. (1993) 120(1-2):63–70.
   PubMed Web of Science ®Google Scholar
• THURMAN GB, PAGE DL, WAMIL BD et al.: Acute inflam-matory changes in subcutaneous microtumors in the ears of mice induced by intravenous CM101 (GBS toxin). J. Cancer Res. Clin. Oncol. (1996) 122(9):549–553.
   PubMed Web of Science ®Google Scholar
• HARRIS AL: Clinical trials of anti-vascular agent group B Streptococcus toxin (CM101). Angiogenesis (1997) 1:36–37.
   PubMedGoogle Scholar
• DEVORE RF, HELLERQVIST CG, WALKEFIELD GB et al:Phase I study of the antineovascularization drug CM-101. Clin. Cancer Res. (1997) 3:365–372.
   PubMed Web of Science ®Google Scholar
• WAMIL BD, THURMAN GB, SUNDELL HW et al.: Soluble E-selectin in cancer patients as a marker of the thera-peutic efficacy of CM101, a tumor-inhibiting anti-neovascularization agent, evaluated in Phase I clinical trail. J. Cancer Res. Clin. Oncol. (1997) 123(3):173–179.
   PubMed Web of Science ®Google Scholar
• ••This study shows the use of a marker assayed in peripheralblood to monitor antivascular therapy.
   Google Scholar
• SGADARI C, ANGIOLILLO AL, TOSATO G: Inhibition ofangiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood (1996) 87 (9):3877–3882.
   PubMed Web of Science ®Google Scholar
• KERBEL RS, HAWLEY RG: Interleukin 12: newest mem-ber of the antiangiogenesis club. J. Natl Cancer Inst. (1995) 87 (8) :557–559.
   PubMed Web of Science ®Google Scholar
• VIZLER C, ROSATO A, CALDERAZZO F eta].: Therapeuticeffect of interleukin 12 on mouse haemangiosarcomas is not associated with an increased anti-tumour cyto-toxic T-lymphocyte activity. Br. J. Cancer (1998) 77 (4) :656–662.
   Google Scholar
• COUGHLIN CM, SALHANY KE, WYSOCKA M et al. Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhi-bition of angiogenesis. J. Clin. Invest. (1998) 101(6):1441–1452.
   PubMed Web of Science ®Google Scholar
• ••IL-12 synergises with IL–18.
   Google Scholar
• BUKOWKI RM, OLNCKI T, SANDSTROM K et al: Phase I trial of subcutaneous interleukin-12 in patients with metastatic renal cell carcinoma. Proc. Am. Soc. Clin. On-col. (1997) 16:108a.
   Google Scholar
• GOEY SH, AULITZKY W, OGILVIE A et al.: Recombinant human interleukin-12 in metastatic renal cell cancer patients: a Phase I study. Proc. Am. Soc. Clin. Oncol. (1997) 16:435a.
   Google Scholar
• LAMERS C, GRATAMA J, OGILVIE A et al: Exogenous IL-12 induces in vivo IL-10 production, followed by down-regulation of IL-12 activities. Proc. Am. Soc. Clin. Oncol. (1997) 16:435a.
   Google Scholar
• TAHARA H, ZITVOGEL L, STROKUS WJ et al: Antitumor effects in patients with melanoma, head and neck and breast cancer in a Phase I/II clinical trial of interleukin-12. Proc. Am. Soc. Clin. Oncol. (1997) 16:438a.
   Google Scholar
• LOTZE MT, ZITVOGEL L, CAMPBELL R et al: Cytokine gene therapy of cancer using interleukin-12: murine and clinical trials. Ann. NY Acad. Sci. (1996) 795:440–454.
   PubMed Web of Science ®Google Scholar
• KONG HL, CRYSTAL RG: Gene therapy strategies for tu-mor antiangiogenesis. J. Natl. Cancer. Inst. (1998) 90(4)273–286.
   Google Scholar
• ••An update in anti-angiogenic gene therapy strategies.
   Google Scholar
• RODOLFO M, ZILOCCHI C, MELANI C et al. Immunother- apy of experimental metastases by vaccination with interleukin gene-transduced adenocarcinoma cells sharing tumor-associated antigens. Comparison be-tween IL-12 and IL-2 gene transduced tumor cell vac-cines. J. Immunol (1996) 157(12):5536–5542.
   Google Scholar
• RAKHMILEVICH AL, JANSSEN K, TURNER J, CULP J, YANGNS: Cytokine gene therapy of cancer using gene gun technology: superior antitumor activity of interleukin-12. Hum. Gene Ther. (1997) 8 (10 :1303–1311.
   PubMedGoogle Scholar
• NANNI P, ROSSI I, DE GIOVANNI C et al: Interleukin 12gene therapy of MHC-negative murine melanoma me-tastases. Cancer Res. (1998) 58 (6):1225–1230.
   PubMed Web of Science ®Google Scholar
• PARDOLL DM: Cancer vaccine. Nature Med. (1998) 4 (Suppl.):525–531.
   Google Scholar
• ••An up-to-date review on cancer vaccine.
   Google Scholar
• SWAIN SM, PARKER B, WELLSTEIN A et al.: Phase I trial of pentosan polysulfate. Invest. New Drugs (1995) 13(1):55–62.
   PubMed Web of Science ®Google Scholar
• LUSH RM, FIGG WD, PLUDA JM et al.: A Phase I study of pentosan polysulfate sodium in patients with ad-vanced malignancies. Ann. Oncol. (1996) 7(9):939–944.
   PubMed Web of Science ®Google Scholar
• PLUDA JM, SHAY LE, FOLI A et al.: Administration of pen-tosan polysulfate to patients with human immunodefi-ciency virus-associated Kaposi's sarcoma. J. Natl. Cancer Inst. (1993) 85(19):1585–1592.
   PubMed Web of Science ®Google Scholar
• SCHWARTSMANN G, SPRINZ E, KALAKUN L et al.: Phase IIstudy of pentosan polysulfate (PPS) in patients with AIDS-related Kaposi's sarcoma. Tumouri (1996) 82 (4):360–363.
   PubMed Web of Science ®Google Scholar
• MARSHALL JL, WELLSTEIN A, AL-KAWAS F, ANDRIS R,HAWKINS MJ: Phase I trial of orally administered pen-tosan polysulfate (PPS) in patients with advanced ma-lignancies. J. Immunother. (1994) 16:249.
   Google Scholar
• PARKER BW, SWAIN SM, ZUGMAIER G et al. Detectable inhibition of heparin-binding growth factor activity in sera from patients treated with pentosan polysulfate. J. Natl. Cancer Inst. (1993) 85 (13) 1068–1073
   PubMed Web of Science ®Google Scholar
• PEROLLET C, HAN ZC, SAVONA C, CAEN JP, BIKFALVI A: Platelet factor 4 modulates fibroblast growth factor 2 (FGF-2) activity and inhibits FGF-2 dimerization. Blood (1998) 91(9)3289–3299.
   Google Scholar
• ••Recent mechanistic study on PF-4 and angiogenesis.
   Google Scholar
• GENGRINOVITCH S, GREENBERG SM, COHEN T et al.: Platelet factor-4 inhibits the mitogenic activity of VEGF121 and VEGF165 using several concurrent mechanisms. J. Biol. Chem. (1995) 270(25):15059–15065.
   PubMed Web of Science ®Google Scholar
• ••Recent mechanistic study on PF-4 and angiogenesis.
   Google Scholar
• FAN TPD: Angiosuupressive therapy for cancer. Trends Pharmacol. Sci. (1994) 15:33–36.
   PubMed Web of Science ®Google Scholar
• ••A summary of anti-angiogenic agents in trial before 1994.
   Google Scholar
• BELMAN N, BONNEM EM, HARVEY HA, LIPTON A: Phase I trial of recombinant platelet factor 4 (rPF4) in patients with advanced colorectal carcinoma. Invest. New Drugs (1996) 14(4)387–389.
   Google Scholar
• PHILIP PA, HARRIS AL: Potential for protein kinase C in-hibitors in cancer therapy. Cancer Treat. Res. (1995) 78:3–27.
   PubMedGoogle Scholar
• OIKAWA T, SHIMAMURA M, ASHIRO H et al.: Inhibitionof angiogenesis by staurosporine, a potent protein ki-nase inhibitor. J. Antibiotics (1992) 45:1155–1160.
   PubMed Web of Science ®Google Scholar
• LI J, HAMPTON JP, MORGAN JP, SIMONS M: Stretch-induced VEGF expression in the heart. J. Clin. Invest. (1997) 100:18–24.
   PubMed Web of Science ®Google Scholar
• PHILIP PA, READ, THAVASU P et al: Phase I study of bry-ostatin 1: assessment of interleukin 6 and tumor ne-crosis factor alpha induction in vivo. The Cancer Research Campaign Phase I Committee. J. Natl. Cancer Inst. (1993) 85(22):1812–1818.
   PubMed Web of Science ®Google Scholar
• PRENDIVILLE J, CROWTHER D, THATCHER N et al.: APhase I study of intravenous bryostatin 1 in patients with advanced cancer. Br. J. Cancer (1993) 68(2)418–424.
   Google Scholar
• JAYSON GC, CROWTHER D, PRENDIVILLE J et al.: A PhaseI trial of bryostatin 1 in patients with advanced malig-nancy using a 24 hour intravenous infusion. Br. J. Can-cer (1995) 72(2):461–468.
   PubMed Web of Science ®Google Scholar
• VARTERASIAN ML, MOHAMMAD RM, EILENDER DS et al.:Phase I study of bryostatin 1 in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. J. Clin. Oncol. (1998) 16(1):56–62.
   PubMed Web of Science ®Google Scholar
• GRANT S, ROBERTS J, POPLIN E et al.: Phase lb trial of bryostatin 1 in patients with refractory malignancies. Clin. Cancer Res. (1998) 4(3):611–618.
   PubMed Web of Science ®Google Scholar
• VAN DER HEM KG, SCHUURHUIS GJ, DRAGER AM, OD-DING JH, HUIJGENS PC: Heterogenous effects of bry-ostatin on human myeloid leukemia clonogenicity: dose and time scheduling dependency. Leuk. Res. (1996) 20(9)743–750.
   Google Scholar
• MCGOWN AT, JAYSON G, PETTIT GR et al: Bryostatin 1-tamoxifen combinations show synergistic effects on the inhibition of growth of P388 cells in vitro. Br. J. Cancer (1998) 77(2):216–220.
   PubMed Web of Science ®Google Scholar
• BIGNAMI GS, WAGNER F, GROTHAUS PG et al.: Biologi-cal activity of 26-succinylbryostatin 1. Biochim. Bio-phys. Acta (1996) 1312(3):197–206.
   PubMed Web of Science ®Google Scholar
• PEARSON JM, VEDAGIRI M: Treatment of moderately se-vere erythema nodosum leprosum with thalidomide - a double-blind controlled trial. Lepr. Rev. (1969) 40(2):111–116.
   PubMedGoogle Scholar
• D'AMATO RJ, LOUGHNAN MS, FLYNN E, FOLKMAN J: Tha-lidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. ScL USA (1994) 91 (9):4082–4085.
   PubMed Web of Science ®Google Scholar
• KENYON BM, BROWNE F, D'AMATO RJ: Effects of tha-lidomide and related metabolites in a mouse corneal model of neovascularization. Exp. Eye Res. (1997) 64(6) :971–978.
   PubMed Web of Science ®Google Scholar
• BORGSTROM P, BOURDON MA, HILLAN KJ, SRIRAMARAO P, FERRARA N: Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angio-genesis and growth of human prostate carcinoma mi-cro tumors in vivo. Prostate (1998) 35(1):1–10.
   PubMed Web of Science ®Google Scholar
• KIM KJ, LI B, WINER J et al.: Inhibition of vascular endo-thelial growth factor-induced angiogenesis sup-presses tumour growth in vivo. Nature (1993) 362 (6423):841–844.
   PubMed Web of Science ®Google Scholar
• CASTELLANI P, VIALE G, DORCARATTO A et al.: The fl-bronectin isoform containing the ED-B oncofetal do-main: a marker of angiogenesis. Int. J. Cancer (1994) 59(5):612–618.
   PubMed Web of Science ®Google Scholar
• MARIANI G, LASKU A, BALZA E et al. Tumor targeting potential of the monoclonal antibody BC-1 against on-cofetal flbronectin in nude mice bearing human tumor implants. Cancer (1997) 80(Suppl 12):2378–2384.
   PubMed Web of Science ®Google Scholar
• HUANG X, MOLEMA G, KING S et al.: Tumor infarction in mice by antibody - directed targeting of tissue factor to tumor vasculature. Science (1997) 275 (5299) 547–550.
   PubMed Web of Science ®Google Scholar
• ••The use of co-aguligands to produce tumour necrosis pro-vides a novel approach to vascular targeting.
   Google Scholar
• BURROWS FJ, THORPE PE: Eradication of large solid tu-mors in mice with an immunotoxin directed against tumor vasculature. Proc. Natl. Acad. Sci. USA (1993) 90(19)8996–9000.
   Google Scholar
• ••The key paper demonstrating proof of principle that vaculartargeting is effective, specific and safe.
   Google Scholar
• BREKKEN RA, HUANG X, KING SW, THORPE PE: Vascular endothelial growth factor as a marker of tumor endo-thelium. Cancer Res. (1998) 58 (9):1952–1959.
   PubMed Web of Science ®Google Scholar
• SKOBE M, ROCKWELL P, GOLDSTEIN N, VOSSELER S, FUSENIG NE: Halting angiogenesis suppresses carci-noma cell invasion. Nature Med. (1997) 3 (11) :1222–1227.
   PubMed Web of Science ®Google Scholar
• ••First demonstration that angiogenesis has a role in local in-vasion as well as growth and metastasis.
   Google Scholar
• WICKHAM TJ, HASKARD D, SEGAL D, KOVESDI I: Target-ing endothelium for gene therapy via receptors up-regulated during angiogenesis and inflammation. Cancer Immunol. Immunother. (1997) 45(3/4):149–151.
   Google Scholar
• EPSTEIN AL, CHEN FM, TAYLOR CR: A novel method for the detection of necrotic lesions in human cancers. Cancer Res. (1988) 48(205842–5848.
   Google Scholar
• MILLER GK, NAEVE GS, GAFFAR SA, EPSTEIN AL: Immu-nologic and biochemical analysis of TNT-1 and TNT-2 monoclonal antibody binding to histones. Hybridoma (1993) 12 (6):689–698.
   PubMed Web of Science ®Google Scholar
• CHEN FM, EPSTEIN AL, LIZ, TAYLOR CR: A comparative autoradiographic study demonstrating differential in-tratumor localization of monoclonal antibodies to cell surface (Lyrn-1) and intracellular (TNT-1) antigens. J. Nucl. Med. (1990) 31(6):1059–1066.
   PubMed Web of Science ®Google Scholar
• RICE GC, STRINGER C, LET et al.: CT-2584: a novel anti-cancer therapeutic with differential cytotoxic activity against a wide variety of tumor cell types compared to normal cells. Blood (1994) 84(10 Suppl. 1):646A.
   Google Scholar
• MARUCCI L, VARTICOVSKI L, ARIAS IM: Effect of a xan-thine analog on human hepatocellular carcinoma cells (Alexander) in culture and in xenografts in SCID mice. Hepatology (1997) 26 (5) :1195–1202.
   PubMed Web of Science ®Google Scholar
• CLARKE E, LET, JENKINS N eta].: CT-2584, a novel anti-tumor agent is cytotoxic to hematologic and epithelial tumor cell lines but not to normal hematopoietic cells. Exp. Hematol. (1994) 22(8):833.
   Google Scholar
• MOORE KS, WEHRLI S, RODER H et al.: Squalamine: an aminosterol antibiotic from the shark. Proc. Natl. Acad. ScL USA (1993) 90(4):1354–1358.
   PubMed Web of Science ®Google Scholar
• SELINSKY BS, ZHOU Z, FOJTIK KG et al.: The aminosterol antibiotic squalamine permeabilizes large unilamellar phospholipid vesicles. Biochim. Biophys. Acta (1998) 1370(2):218–234.
   PubMed Web of Science ®Google Scholar
• KIKUCHI K, BERNARD EM, SADOWNIK A, REGEN SL, ARMSTRONG D: Antimicrobial activities of squalamine mimics. Antimicrob. Agents Chemother. (1997) 41 (7) :1433–1438.
   PubMed Web of Science ®Google Scholar
• TILTON, RG, DIXON RAF, BROCK TA: Growth factor an-tagonists for the treatment of diabetic vascular compli-cations. Exp. Opin. Invest. Drugs (1997) 6(11):1671–1684.
   PubMedGoogle Scholar
• ECKHARDT SG, BURRIS HA, ECKARDT JR et al.: A Phase I clinical and pharmacokinetic study of the angiogene-sis inhibitor, tecogalan sodium. Ann. Oncol. (1996) 7 (5):491–496.
   PubMed Web of Science ®Google Scholar
• MURATA T, ISHIBASHI T, YOSHIKAWA H, KHALIL A, INO-MATA H: Tecogalan sodium inhibits corneal neovascu-larization induced by basic fibroblast growth factor. Ophthalmic Res. (1995) 27(6)330–334.
   Google Scholar
• BABA M, SHIGETA S, IKEUCHI T, KORENAGA H, OSADA Y: Anti-angiogenesis agent DS-4152 is a potent and se-lective inhibitor of 11IV-1 replication in vitro. AIDS (1994) 8(0:43–48.
   PubMedGoogle Scholar
• KURBACHER CM, BRUCKNER HW, ANDREOTTI PE et al. In vitro activity of titanocenedichloride versus cis-platin in four ovarian carcinoma cell lines evaluated by a microtiter plate ATP bioluminescence assay. Anti-cancer Drugs (1995) 6(5):697–704.
   PubMed Web of Science ®Google Scholar
• KURBACHER CM, NAGEL W, MALLMANN P et al. In vitro activity of titanocenedichloride in human renal cell carcinoma compared to conventional antineoplastic agents. Anticancer Res. (1994) 14(4A):1529–1533.
   Google Scholar
• BASTAKI M, MISSIRLIS E, KLOURAS N, KARAKIULAKIS G, MARAGOUDAKIS ME: Suppression of angiogenesis by the antitumor agent titanocene dichloride. Eur. J. Phar-macol. (1994) 251 (2-3):263–269.
   PubMed Web of Science ®Google Scholar
• MARAGOUDAKIS ME, PERISTERIS P, MISSIRLIS E et al: In-hibition of angiogenesis by anthracyclines and titano-cene dichloride. Ann. NY Acad. Sci. (1994) 732:280–293.
   PubMed Web of Science ®Google Scholar
• CHERESH DA: Death to a blood vessel, death to a tumor. Nature Med. (1998) 4(4):395–396.
   PubMed Web of Science ®Google Scholar
• ••Recent commentary on (anti-)angiogenesis.
   Google Scholar
• GUTHLEIL JC et al.: Phase I study of vitaxin, an anti-angiogenic humanized monoclonal antibody to vascu-lar integrin av63. Proc. Am. Soc. Clin. Oncol. (In Press.)
   Google Scholar
• BROOKS PC, SILLETTI S, VON SCHALSCHA TL, FRIED-LANDER M, CHERESH DA: Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity. Cell (1998) 92(3) :391–400.
   PubMed Web of Science ®Google Scholar
• ••A novel encrypted protein fragment with anti-angiogenicactivity.
   Google Scholar
• SIPKINS DA, CHERESH DA, KAZEMI MR et al.: Detection of tumor angiogenesis in vivo by a33-targeted mag-netic resonance imaging. Nature Med. (1998) 5:623–626.
   Google Scholar
• O'REILLY MS, HOLMGREN L, SHING Y et al. Angiostatin: a novel angiogenesis inhibitor that mediates the sup-pression of metastases by a Lewis lung carcinoma. Cell (1994) 79(2):315–328.
   Google Scholar
• O'REILLY MS, BOEHM T, SHING Y et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell (1997) 88(2):277–285.
   Google Scholar
• KOHN EC: Endostatin and angiostatin: the next anti-angiogenesis generation. Angiogenesis (1998) 2(1)25–27.
   Google Scholar
• ••Recent commentary on angiostatin and endostatin.
   Google Scholar
• SIM BK: Angiostatin and Endostatin': endothelial cell-specific endogenous inhibitors of angiogenesis and tumor growth. Angiogenesis (1998) 2 (1) :37–48.
   PubMedGoogle Scholar
• Comprehensive review on angiostatin and endostatin.
   Google Scholar
• CAO Y, O'REILLY MS, MARSHALL B et al.: Expression of angiostatin cDNA in a murine fibrosarcoma sup-presses primary tumor growth and produces long-term dormancy of metastases. J. Clin. Invest. (1998) 101(5)1055–1063.
   Google Scholar
• BOEHM T, FOLKMAN J, BROWDER T, O'REILLY MS: Anti-angiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature (1997) 390(6658)404–407.
   Google Scholar
• O'REILLY MS, HOLMGREN L, CHEN C, FOLKMAN J: An-giostatin induces and sustains dormancy of human primary tumors in mice. Nature Med. (1996) 2(6)689–692.
   Google Scholar
• FOTSIS T, ZHANG Y, PEPPER MS et al. The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppress tumour growth. Nature (1994) 368(6468) 237–239
   PubMed Web of Science ®Google Scholar
• FOX SB, HARRIS AL: Markers of angiogenesis: clinical applications in prognosis and anti-angiogenic ther-apy. Invest. New Drugs (1997) 15:15–28.
   PubMed Web of Science ®Google Scholar
• ••Detailed discussion of surrogate markers and methods to as-sess inhibition of angiogenesis in trials.
   Google Scholar
• FOX SB, LEEK RD, BLISS J et al.: Association of tumor angiogenesis with bone marrow micrometastasies in breast cancer patients. J. Natl. Cancer Inst. (1997) 89:1044–1049.
   PubMed Web of Science ®Google Scholar
• ••Demonstration that high vessel density in primary tumoursis a marker for early metastasis.
   Google Scholar
• SCHLIMOK G, PANTEL K, LOIBNER H, FACKLER-SCHWALBE I, RIETHMULLER G: Reduction of metastatic carcinoma cells in bone marrow by intravenously ad-ministered monoclonal antibody: towards a novel sur-rogate test to monitor adjuvant therapies of solid tumours. Eur. J. Cancer (1995) 31A (11) :1799–1803.
   PubMedGoogle Scholar
• ••A potential method to monitor anti-angiogenic therapy byclearance of micrometastases from the marrow.
   Google Scholar
• RELF M, LEJEUNE S, SCOTT PA et al.: Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotro-phin in human primary breast cancer and its relation to angiogenesis. Cancer Res. (1997) 57 (5):963–969.
   PubMed Web of Science ®Google Scholar
• ••An expression profile of angiogenic factors in primary breastcancer.
   Google Scholar
• PEZZELLA F, PASTORINO U, TAGLIABUE E et al.: Non-small-cell lung carcinoma tumor growth without mor-phological evidence of neo-angiogenesis. Am. J. Pathol (1997) 151(5):1417–1423.
   PubMed Web of Science ®Google Scholar
• ••On novel mechanisms of non-angiogenesis growth oftumours.
   Google Scholar
• NELSON NJ: Inhibitors of angiogenesis enter Phase III testing. J. Nati Cancer Inst. (1998) 90(13):NEWS 692–693.
   Google Scholar